Celgene Revlimid Post-Market Phase III Study To Explore Lower Dose
Celgene's Phase III study for its myelodysplastic syndromes therapy Revlimid will examine lower doses, the company told FDA's Oncologic Drugs Advisory Committee on Sept. 14
Celgene's Phase III study for its myelodysplastic syndromes therapy Revlimid will examine lower doses, the company told FDA's Oncologic Drugs Advisory Committee on Sept. 14